Sales of Lilly’s top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter of ...

Novo Nordisk A/S NVO reported fourth-quarter 2024 earnings of 91 cents per American Depositary Receipt (ADR), which beat the ...

The company’s shares rose as investors breathed a sigh of relief on strong sales growth and guidance, despite ongoing ...

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...

A NEW SET OF TARIFFS BY THE TRUMP ADMINISTRATION WILL TAKE EFFECT, AND THEY COULD DRAMATICALLY CHANGE THE WAY YOU GET ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Medicare beneficiaries may pay less for 15 additional prescription drugs as early as 2027 as part of the next round of federal regulators' price negotiations with pharmaceutical manufacturers.

Proposed changes to this list are open for consultation. Learn about the consultation and how to provide your feedback. The consultation closes on March 8, 2025. Drugs included on the list for ...

China’s healthcare regulator has pledged to investigate the quality of drugs under a new list covered by national ... for high blood pressure and diabetes or anaesthetics”, Caixin magazine ...

to its price negotiation list, aiming to save billions. Incoming Trump administration will finalize details, but obesity treatment remains uncovered under Medicare rules. Listen to Story WASHINGTON: ...

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

The Biden administration, in its last full weekday in office, announced the next 15 drugs up for Medicare price negotiation. Blockbuster diabetes drug Ozempic is on the list. That means the ...